This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting antivirals (DAAs) or older interferon-based therapy, according to study results presented at the 2017 AASLD Liver Meeting last week in Washington, DC.
“It doesn’t matter how you eradicate hepatitis C, you get a similar reduction in liver cancer,” George Ioannou of the University of Washington told reporters at an AASLD press briefing.
Advanced liver damage is typically not fully reversible even after HCV is cured, so people who already have cirrhosis when they undergo treatment remain at ongoing risk for HCC. As expected, liver cancer was most likely to occur among people who both had cirrhosis and were not cured (with an incidence rate of 3.25 per 100 person-years), followed by those with cirrhosis who achieved SVR (1.97 per 100 person-years), people without cirrhosis who were not cured (0.87 per 100 person-years) and people with no cirrhosis and SVR (0.24 per 100 person-years).
Read more…http://www.aidsmap.com/page/3186146/